MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on December 14, 2019, 04:59:16 pm

Title: (Abst.) Safety and efficacy of autologous HSCT for MS in Norway
Post by: agate on December 14, 2019, 04:59:16 pm
This is a small study (30 patients) but the finding that some patients had amenorrhea lasting more than 12 months and ovarian failure would be a concern.


From PubMed (December 14, 2019), "Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway":


https://www.ncbi.nlm.nih.gov/pubmed/31833798